Does Metformin and/or Mediterrenean Diet Work in People with Metabolic Syndrome to Help Avoid Aging Associated Diseases?
#
OBJECTIVE
The Metformin and Dietary Restriction to Prevent Age-Related Morbid Events in People With Metabolic Syndrome (MeMeMe) trial tested whether 1,700 mg/day metformin (MET) with or without a Mediterranean diet (MedDiet) intervention could reduce the cumulative incidence of major noncommunicable diseases in people with metabolic syndrome.
RESEARCH DESIGN AND METHODS
A total of 1,442 participants were randomly assigned to one of four interventions: 1) MET (1,700 mg/day) plus MedDiet intervention (MET+MedDiet); 2) placebo plus MedDiet intervention; 3) MET (1,700 mg/day) alone; and 4) placebo alone. Participants were followed up for 3 years on average. The primary outcome was the cumulative incidence of major noncommunicable diseases (including type 2 diabetes, cardiovascular diseases, and cancer). Secondary outcomes were the incidence of type 2 diabetes and the changing prevalence of metabolic syndrome.
RESULTS
The crude incidence of the major noncommunicable diseases was 6.7 cases per 100 person-years in the MET+MedDiet group, 6.9 in the MET alone group, 13.3 in the placebo plus MedDiet group, and 11.3 in the placebo group. The differences were fully explained by the reduction of type 2 diabetes, which was 80% and 92% lower in the MET and MET+MedDiet groups, respectively, compared with placebo.
CONCLUSIONS
The use of 1,700 mg/day MET is effective to prevent diabetes in people selected on the basis of metabolic syndrome.
My comment: I think this is a landmark study. On the negative side, mediterrenean diet convincingly failed here perhaps due to lack of adherence or something else. Metformin also showed no heart disease or cancer preventative effects, which will come as a surprise to longevity community.
Introduction and Study Rationale
Noncommunicable diseases (NCDs), such as type 2 diabetes, cardiovascular disease, and cancer, represent a leading cause of mortality, accounting for nearly 90% of deaths in Europe. A primary driver for these conditions is metabolic syndrome (MetS), a cluster of risk factors including abdominal obesity, high blood pressure, dyslipidemia (abnormal cholesterol and triglycerides), and elevated fasting blood sugar. The presence of MetS dramatically increases an individual's risk for developing other serious health problems, including a fivefold higher risk of type 2 diabetes and a twofold higher risk of cardiovascular diseases.
Two key strategies have been proposed to mitigate these risks: lifestyle changes and pharmacological intervention. The Mediterranean diet (MedDiet), rich in unrefined grains, legumes, vegetables, fruits, and olive oil, has been shown to improve cardiometabolic health and even reverse MetS. On the other hand, metformin (MET), a widely used first-line drug for type 2 diabetes, is known as a "calorie-restriction mimetic" and has shown potential protective effects against a range of age-related diseases beyond diabetes.
Against this backdrop, the Metformin and Dietary Restriction to Prevent Age-Related Morbid Events in People With Metabolic Syndrome (MeMeMe) trial was designed. It is a large-scale, randomized controlled trial aimed at answering a critical question: Can treatment with 1,700 mg/day of metformin, either alone or in combination with a Mediterranean diet intervention, reduce the overall incidence of major NCDs in older adults (50-79 years) with metabolic syndrome?
Research Design and Methods
The MeMeMe trial was a robustly designed 2 × 2 factorial randomized controlled trial conducted at a single center in Milan, Italy. It was registered (EudraCT no. 2012–005427-32; ClinicalTrials.gov identifier NCT02960711) and received full ethical approval.
Study Population
The trial recruited 1,994 volunteers, from which 1,442 participants aged 50-79 years with a confirmed diagnosis of MetS were ultimately randomized. MetS was defined by the presence of at least three of the following five criteria, using modified waist circumference thresholds:
- High Blood Pressure: ≥130/85 mmHg or use of antihypertensive medication.
- High Fasting Glucose: Fasting plasma glucose ≥100 mg/dL.
- High Triglycerides: ≥150 mg/dL or use of triglyceride-lowering medication.
- Low HDL Cholesterol: <40 mg/dL for men and <50 mg/dL for women.
- Large Waist Circumference: ≥100 cm for men and ≥85 cm for women.
Key exclusion criteria included a prior diagnosis of diabetes, fasting glucose ≥126 mg/dL on two tests, severe kidney, heart, or liver insufficiency, or a cancer diagnosis within the previous five years.
Interventions and Randomization
Participants were randomly allocated into one of four groups in a 2x2 factorial design:
- MET + MedDiet: 1,700 mg/day metformin plus Mediterranean diet intervention (n=358).
- Placebo + MedDiet: Placebo plus Mediterranean diet intervention (n=368).
- MET alone: 1,700 mg/day metformin plus placebo diet intervention (n=373).
- Placebo alone: Placebo plus placebo diet intervention (n=343).
The randomization was a two-step, stratified process. The dietary assignment was a cluster randomization (families were kept in the same group), while the drug assignment (metformin vs. placebo) was individual, double-blind, and stratified by sex and age.
The metformin treatment involved a gradual dose increase to ensure tolerance: 500 mg/day for the first month, 850 mg/day for the next two months, and finally the full dose of 1,700 mg/day (850 mg twice daily). The dietary intervention was qualitative, not calorie-restricted. Participants in the MedDiet groups were encouraged to consume satiating, high-fiber foods (whole grains, legumes) and reduce high-glycemic foods (sugar, refined flour) and saturated fats. This was supported by monthly activities like cooking classes and community meals in the first year.
Outcome Measurements and Analysis
The primary outcome was the cumulative incidence of major NCDs, defined as a composite of type 2 diabetes, cardiovascular diseases (coronary heart disease, stroke), and cancer. Secondary outcomes included the incidence of type 2 diabetes alone and changes in the prevalence of MetS and its components.
Participants were followed for an average of 3 years. The primary analysis was conducted on an intention-to-treat basis, using Cox proportional hazards models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs).
Key Result
Participant Characteristics and Intervention Effects
The average age of participants was 62.5 years. At baseline, the most common components of MetS were low HDL cholesterol (97%), high blood pressure (96%), and large waist circumference (90%). The four groups were well-matched in their baseline characteristics. Treatment adherence was reasonable, with participants receiving an average dose of ~1,400 mg/day of metformin or placebo.
After one year, the groups receiving metformin showed significant improvements:
- MET alone and MET+MedDiet groups experienced significant reductions in body weight, BMI, waist circumference, and fasting glycemia compared to the placebo group.
- The MET+MedDiet group also showed a significant reduction in total and LDL cholesterol.
- The MedDiet intervention alone was ineffective in producing significant changes in most metabolic markers compared to placebo. Furthermore, analysis of food diaries revealed that the dietary intervention did not lead to significant, sustained changes in dietary habits, as measured by a "Dietary Index."
Primary and Secondary Outcomes
The study's most significant findings relate to the incidence of disease over the follow-up period.
- Overall NCDs: The cumulative incidence of all NCDs was significantly lower in the metformin groups. The crude incidence rates were 6.7 and 6.9 cases per 100 person-years in the MET+MedDiet and MET alone groups, respectively, compared to 13.3 and 11.3 in the Placebo+MedDiet and Placebo alone groups.
- Compared to placebo, the adjusted HR for NCDs was 0.48 (95% CI, 0.29–0.82) for the MET+MedDiet group and 0.51 (95% CI, 0.30–0.86) for the MET alone group.
- The MedDiet alone showed no protective effect (HR 1.09).
- Source of the Effect: This remarkable reduction in overall NCDs was fully explained by the prevention of type 2 diabetes. There was no statistically significant difference in the incidence of cardiovascular diseases or cancer across the four groups.
- Prevention of Type 2 Diabetes: The effect of metformin on diabetes prevention was dramatic. Over the course of the study, there were 48 new cases of diabetes in the placebo groups combined, compared to only 7 cases in the metformin groups combined.
- Compared to placebo, metformin reduced the incidence of type 2 diabetes by 80% in the MET alone group (HR 0.20; 95% CI, 0.10–0.55).
- The combination of metformin and the MedDiet was even more effective, reducing diabetes incidence by 92% (HR 0.08; 95% CI, 0.02–0.35). This effect was consistent even in participants who did not have significantly elevated fasting glucose at baseline.
- Cancer Mortality: An unexpected and concerning finding was an excess of cancer-related deaths in the metformin-treated groups (6 deaths) compared to none in the placebo groups. The authors note that these deaths were from six different types of cancer and that some of the participants had poor adherence to the treatment. They conclude this finding is likely due to chance but warrants further investigation.
Conclusions and Implications
The MeMeMe trial provides powerful evidence for the role of metformin in primary prevention.
- Metformin is Highly Effective for Diabetes Prevention: The study's primary conclusion is that 1,700 mg/day of metformin is exceptionally effective at preventing the onset of type 2 diabetes in people selected on the basis of having metabolic syndrome. The 80-92% risk reduction observed is substantially greater than the 31% reduction reported in the landmark Diabetes Prevention Program (DPP), highlighting its potent effect in this specific high-risk population.
- The MedDiet Intervention Was Insufficient: The dietary intervention, as designed for this trial (e.g., monthly group activities), was not intensive enough to induce significant changes in dietary behavior or health outcomes on its own. However, the data suggest a potential synergistic effect, as the MET+MedDiet group showed the best overall improvements in metabolic parameters and the greatest reduction in diabetes risk, even if the difference from the MET alone group was not statistically significant.
- A Call to Revise Clinical Guidelines: The authors argue that these results strongly support the use of metformin as a safe, effective, and low-cost tool for primary prevention of diabetes. In many countries, including Italy where the trial was conducted, metformin is not recommended or prescribed for prevention in people with MetS or prediabetes. The MeMeMe trial's findings provide a compelling case to reconsider these clinical guidelines and expand metformin's indication to include high-risk individuals without a diabetes diagnosis.
- Limitations and Future Directions: The authors acknowledge several limitations, including the lack of oral glucose tolerance testing (which may have led to under-diagnosis of diabetes in the MET groups) and the failure to reach the original enrollment target. The anomalous finding regarding cancer mortality also requires careful monitoring in future follow-ups. The research team plans to continue active follow-up of the cohort to assess the long-term impact of metformin on the prevention of a broader range of NCDs.
In summary, the MeMeMe trial demonstrates that in individuals with metabolic syndrome, metformin offers profound protection against the development of type 2 diabetes. This effect is far more significant than that of the low-intensity lifestyle intervention tested and establishes a strong rationale for using metformin as a key strategy in public health efforts to curb the diabetes epidemic.
Paper · Diabetes CareMetformin Treatment With or Without Mediterraneandiabetesjournals.org

